Trial Profile
An Open-Label, Randomized, Crossover Study to Assess the Pharmacokinetic and Pharmacodynamic Profiles of Once Daily and Twice Daily Dose Regimens of Recombinant Human Parathyroid Hormone (rhPTH[1-84]) Administered Subcutaneously to Subjects With Hypoparathyroidism
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Parathyroid hormone (Primary) ; Calcium
- Indications Hypoparathyroidism
- Focus Pharmacokinetics
- Acronyms PARALLAX
- Sponsors Shire; Takeda
- 27 Mar 2019 Status changed from recruiting to completed.
- 13 Dec 2017 Planned End Date changed from 1 Dec 2017 to 31 May 2019.
- 13 Dec 2017 Planned primary completion date changed from 1 Dec 2017 to 31 May 2019.